Pyxis Oncology, Inc. (PYXS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PYXS's 50-day simple moving average crossed above ...
Though Pyxis Oncology Inc.’s preliminary phase I data with antibody-drug conjugate (ADC) PYX-201 in solid tumors were characterized as positive, findings sent the Boston-based firm’s stock ...
Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month. The Boston biotech is ...
On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback